Literature DB >> 12794119

Differentiation of monocytic cell clones into CD8 alpha+ dendritic cells (DC) suggests that monocytes can be direct precursors for both CD8 alpha+ and CD8 alpha- DC in the mouse.

Jian-Xin Gao1, Xingluo Liu, Jing Wen, Huiming Zhang, Joan Durbin, Yang Liu, Pan Zheng.   

Abstract

Dendritic cells (DC) are the professional APCs that initiate T cell immune responses. DC can develop from both myeloid and lymphoid progenitors. In the mouse, the CD8alpha(+) DC had been designated as "lymphoid" DC, and CD8alpha(-) DC as "myeloid" DC until recently when it was demonstrated that common myeloid progenitors can also give rise to CD8alpha(+) DC in bone marrow chimera mice. However, it is still not clear which committed myeloid lineages differentiate into CD8alpha(+) DC. Because monocytes can differentiate into DC in vivo, the simplest hypothesis is that the CD8alpha(+) DC can be derived from the monocyte/macrophage. In this study we show that cell clones, isolated from CD8alpha(+) DC lymphoma but with a monocytic phenotype (CD11c(low/-)D11b(high)CD8alpha(-)I-A(low)), can redifferentiate into CD8alpha(+) DC either when stimulated by LPS and CD40L or when they migrate into the lymphoid organs. Maturation of DC in vivo correlated with strong priming of allogeneic T cells. Moreover, the monocytes from cultured splenocytes or peritoneal exudates macrophages of wild-type mice are also capable of differentiating into CD11c(+)CD8alpha(+) DC after their migration into the draining lymph nodes. Our results suggest that monocytes can be direct precursors for CD11c(+)CD8alpha(+) DC in vivo. In addition, the monocyte clones described in this study may be valuable for studying the differentiation and function of CD8alpha(+) DC that mediate cross-presentation of Ag to CD8 T cells specific for cell-associate Ags.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12794119     DOI: 10.4049/jimmunol.170.12.5927

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  TL and CD8αα: Enigmatic partners in mucosal immunity.

Authors:  Danyvid Olivares-Villagómez; Luc Van Kaer
Journal:  Immunol Lett       Date:  2010-09-17       Impact factor: 3.685

2.  Piwil2 expressed in various stages of cervical neoplasia is a potential complementary marker for p16.

Authors:  Gang He; Li Chen; Yin Ye; Yi Xiao; Keding Hua; David Jarjoura; Toru Nakano; Sanford H Barsky; Rulong Shen; Jian-Xin Gao
Journal:  Am J Transl Res       Date:  2010-03-25       Impact factor: 4.060

3.  Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker.

Authors:  James J Liu; Rulong Shen; Li Chen; Yin Ye; Gang He; Keding Hua; David Jarjoura; Toru Nakano; Ganju K Ramesh; Charles L Shapiro; Sanford H Barsky; Jian-Xin Gao
Journal:  Int J Clin Exp Pathol       Date:  2010-03-20

4.  Identification of Piwil2-like (PL2L) proteins that promote tumorigenesis.

Authors:  Yin Ye; De-Tao Yin; Li Chen; Quansheng Zhou; Rulong Shen; Gang He; Qingtao Yan; Zhenyu Tong; Andrew C Issekutz; Charles L Shapiro; Sanford H Barsky; Haifan Lin; Jian-Jian Li; Jian-Xin Gao
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

5.  Precancerous stem cells have the potential for both benign and malignant differentiation.

Authors:  Li Chen; Rulong Shen; Yin Ye; Xin-An Pu; Xingluo Liu; Wenrui Duan; Jing Wen; Jason Zimmerer; Ying Wang; Yan Liu; Larry C Lasky; Nyla A Heerema; Danilo Perrotti; Keiko Ozato; Satomi Kuramochi-Miyagawa; Toru Nakano; Allen J Yates; William E Carson; Haifan Lin; Sanford H Barsky; Jian-Xin Gao
Journal:  PLoS One       Date:  2007-03-14       Impact factor: 3.240

6.  Precancerous stem cells can serve as tumor vasculogenic progenitors.

Authors:  Rulong Shen; Yin Ye; Li Chen; Qingtao Yan; Sanford H Barsky; Jian-Xin Gao
Journal:  PLoS One       Date:  2008-02-20       Impact factor: 3.240

Review 7.  Cancer stem cells: the lessons from pre-cancerous stem cells.

Authors:  Jian-Xin Gao
Journal:  J Cell Mol Med       Date:  2007-12-05       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.